Page last updated: 2024-11-06

phenylalanylphenylalanylamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID85169
CHEMBL ID108438
MeSH IDM0063533

Synonyms (18)

Synonym
h-phe-phe-nh2
(s)-2-amino-n-((s)-1-carbamoyl-2-phenyl-ethyl)-3-phenyl-propionamide
bdbm50188489
phenylalanylphenylalanylamide
CHEMBL108438 ,
15893-46-6
l-phenylalanyl-l-phenylalaninamide
(2s)-2-amino-n-[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]-3-phenylpropanamide
l-phenylalanine-l-phenylalanylamide
l-phe-l-phe-amide
phe-phe-amide
l-phenylalaninamide, l-phenylalanyl-
XXPXQEQOAZMUDD-HOTGVXAUSA-N
phenylalanyl-phenylalanine amide
(s)-2-amino-n-((s)-1-amino-1-oxo-3-phenylpropan-2-yl)-3-phenylpropanamide
AKOS040753525
(2s)-2-[(2s)-2-amino-3-phenylpropanamido]-3-phenylpropanamide
MQ5FV9R7B9

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Unfortunately, the pharmacophore of this compound was accompanied by a poor pharmacokinetic (PK) profile."( Exploration and pharmacokinetic profiling of phenylalanine based carbamates as novel substance p 1-7 analogues.
Artursson, P; Bylund, J; Carlsson-Jonsson, A; Fransson, R; Hallberg, M; Kratz, JM; Nordvall, G; Sandström, A; Svensson, R, 2014
)
0.4

Bioavailability

ExcerptReferenceRelevance
" With the overall aim to develop stable and orally bioavailable SP(1-7) mimetics, the dipeptide was chosen as a lead compound."( Constrained H-Phe-Phe-NH2 analogues with high affinity to the substance P 1-7 binding site and with improved metabolic stability and cell permeability.
Artursson, P; Fransson, R; Hallberg, M; Kratz, JM; Nyberg, F; Sandström, A; Sköld, C; Svensson, R, 2013
)
0.39
" Although, additional structural modifications are needed to achieve compounds exhibiting high/fair bioavailability after oral administration, the examples presented herein demonstrate that the bioactive peptides SP(1-7) and endomorphin-2 can be converted into low molecular weight compounds that are able to mimic the in vivo actions of the heptapeptide SP(1-7)."( From the Anti-Nociceptive Substance P Metabolite Substance P (1-7) to Small Peptidomimetics.
Hallberg, M; Sandstrom, A, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (8)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Substance-P receptorRattus norvegicus (Norway rat)Ki0.00840.00070.12981.0000AID756391
Substance-P receptorHomo sapiens (human)Ki0.00150.00000.79368.7470AID1176514; AID1176535
Solute carrier family 15 member 1Homo sapiens (human)IC50 (µMol)80.00000.18000.19000.2000AID266249
Mu-type opioid receptorCavia porcellus (domestic guinea pig)IC50 (µMol)80.00000.00020.660310.0000AID266249
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 1A2Homo sapiens (human)INH20.00000.10000.10000.1000AID1176533
Cytochrome P450 3A4Homo sapiens (human)INH20.00001.70002.85004.0000AID1176532
Cytochrome P450 2D6Homo sapiens (human)INH20.00003.20003.40003.6000AID1176531
Cytochrome P450 2C9 Homo sapiens (human)INH20.00004.40007.00009.1000AID1176534
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (85)

Processvia Protein(s)Taxonomy
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
aggressive behaviorSubstance-P receptorHomo sapiens (human)
positive regulation of leukocyte migrationSubstance-P receptorHomo sapiens (human)
angiotensin-mediated drinking behaviorSubstance-P receptorHomo sapiens (human)
inflammatory responseSubstance-P receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwaySubstance-P receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationSubstance-P receptorHomo sapiens (human)
tachykinin receptor signaling pathwaySubstance-P receptorHomo sapiens (human)
long-term memorySubstance-P receptorHomo sapiens (human)
associative learningSubstance-P receptorHomo sapiens (human)
detection of abiotic stimulusSubstance-P receptorHomo sapiens (human)
response to ozoneSubstance-P receptorHomo sapiens (human)
positive regulation of epithelial cell migrationSubstance-P receptorHomo sapiens (human)
response to auditory stimulusSubstance-P receptorHomo sapiens (human)
regulation of smooth muscle cell migrationSubstance-P receptorHomo sapiens (human)
positive regulation of synaptic transmission, cholinergicSubstance-P receptorHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicSubstance-P receptorHomo sapiens (human)
response to estradiolSubstance-P receptorHomo sapiens (human)
response to progesteroneSubstance-P receptorHomo sapiens (human)
response to nicotineSubstance-P receptorHomo sapiens (human)
operant conditioningSubstance-P receptorHomo sapiens (human)
sperm ejaculationSubstance-P receptorHomo sapiens (human)
eating behaviorSubstance-P receptorHomo sapiens (human)
positive regulation of vascular permeabilitySubstance-P receptorHomo sapiens (human)
response to ethanolSubstance-P receptorHomo sapiens (human)
positive regulation of action potentialSubstance-P receptorHomo sapiens (human)
positive regulation of blood pressureSubstance-P receptorHomo sapiens (human)
positive regulation of ossificationSubstance-P receptorHomo sapiens (human)
positive regulation of vasoconstrictionSubstance-P receptorHomo sapiens (human)
positive regulation of hormone secretionSubstance-P receptorHomo sapiens (human)
behavioral response to painSubstance-P receptorHomo sapiens (human)
regulation of smooth muscle cell proliferationSubstance-P receptorHomo sapiens (human)
positive regulation of lymphocyte proliferationSubstance-P receptorHomo sapiens (human)
positive regulation of epithelial cell proliferationSubstance-P receptorHomo sapiens (human)
positive regulation of stress fiber assemblySubstance-P receptorHomo sapiens (human)
response to electrical stimulusSubstance-P receptorHomo sapiens (human)
smooth muscle contraction involved in micturitionSubstance-P receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionSubstance-P receptorHomo sapiens (human)
positive regulation of flagellated sperm motilitySubstance-P receptorHomo sapiens (human)
monoatomic ion transportSolute carrier family 15 member 1Homo sapiens (human)
protein transportSolute carrier family 15 member 1Homo sapiens (human)
peptide transportSolute carrier family 15 member 1Homo sapiens (human)
dipeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
tripeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
proton transmembrane transportSolute carrier family 15 member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (39)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
tachykinin receptor activitySubstance-P receptorHomo sapiens (human)
protein bindingSubstance-P receptorHomo sapiens (human)
substance P receptor activitySubstance-P receptorHomo sapiens (human)
proton-dependent oligopeptide secondary active transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
peptide:proton symporter activitySolute carrier family 15 member 1Homo sapiens (human)
tripeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
dipeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (15)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
plasma membraneSubstance-P receptorHomo sapiens (human)
cell surfaceSubstance-P receptorHomo sapiens (human)
dendriteSubstance-P receptorHomo sapiens (human)
sperm flagellumSubstance-P receptorHomo sapiens (human)
cell bodySubstance-P receptorHomo sapiens (human)
sperm headSubstance-P receptorHomo sapiens (human)
sperm midpieceSubstance-P receptorHomo sapiens (human)
plasma membraneSubstance-P receptorHomo sapiens (human)
sperm midpieceSubstance-P receptorHomo sapiens (human)
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
brush borderSolute carrier family 15 member 1Homo sapiens (human)
membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (32)

Assay IDTitleYearJournalArticle
AID756384Apparent permeability from apical to basolateral side in human Caco2 cells at 100 uM after 2 hrs by LC/MS analysis2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Constrained H-Phe-Phe-NH2 analogues with high affinity to the substance P 1-7 binding site and with improved metabolic stability and cell permeability.
AID18532Rate constant for the compound at a substrate concentration of 262 uM was determined2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
The stability of pseudopeptides bearing sulfoximines as chiral backbone modifying element towards proteinase K.
AID162715Amount of proteinase K required to release folin positive amino acids at a substrate concentration of 304 uM2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
The stability of pseudopeptides bearing sulfoximines as chiral backbone modifying element towards proteinase K.
AID1176512Intrinsic clearance in human microsomes2014ACS medicinal chemistry letters, Dec-11, Volume: 5, Issue:12
Exploration and pharmacokinetic profiling of phenylalanine based carbamates as novel substance p 1-7 analogues.
AID266247Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding.
AID18750Relativity constant at a substrate concentration of 262 uM2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
The stability of pseudopeptides bearing sulfoximines as chiral backbone modifying element towards proteinase K.
AID1176511Intrinsic clearance in rat microsomes2014ACS medicinal chemistry letters, Dec-11, Volume: 5, Issue:12
Exploration and pharmacokinetic profiling of phenylalanine based carbamates as novel substance p 1-7 analogues.
AID756386Drug uptake in CHO cells expressing PEPT1 at 100 uM after 15 mins measured per mg of protein by LC/MS analysis2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Constrained H-Phe-Phe-NH2 analogues with high affinity to the substance P 1-7 binding site and with improved metabolic stability and cell permeability.
AID756388Half life in human liver microsomes at 1 uM by LC/MS analysis2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Constrained H-Phe-Phe-NH2 analogues with high affinity to the substance P 1-7 binding site and with improved metabolic stability and cell permeability.
AID1176533Inhibition of CYP1A2 (unknown origin)2014ACS medicinal chemistry letters, Dec-11, Volume: 5, Issue:12
Exploration and pharmacokinetic profiling of phenylalanine based carbamates as novel substance p 1-7 analogues.
AID756387Drug uptake in CHOK1 cells at 100 uM after 15 mins measured per mg of protein by LC/MS analysis2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Constrained H-Phe-Phe-NH2 analogues with high affinity to the substance P 1-7 binding site and with improved metabolic stability and cell permeability.
AID266246Activation of human PEPT1 expressed in MDCK cells2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding.
AID462888Displacement of [3H]SP1-7 from NK1 receptor in Sprague-Dawley rat spinal cord membrane2010Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
Discovery of dipeptides with high affinity to the specific binding site for substance P1-7.
AID266248Ratio of %GSmax to EC50 for human PEPT1 activation2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding.
AID1176514Displacement of [3H]-SP1-7 from NK1 receptor (unknown origin) by scintillation counting analysis2014ACS medicinal chemistry letters, Dec-11, Volume: 5, Issue:12
Exploration and pharmacokinetic profiling of phenylalanine based carbamates as novel substance p 1-7 analogues.
AID756383Apparent permeability from basolateral to apical side in human Caco2 cells at 100 uM after 2 hrs by LC/MS analysis2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Constrained H-Phe-Phe-NH2 analogues with high affinity to the substance P 1-7 binding site and with improved metabolic stability and cell permeability.
AID1176503Drug recovery in human plasma at 10 uM2014ACS medicinal chemistry letters, Dec-11, Volume: 5, Issue:12
Exploration and pharmacokinetic profiling of phenylalanine based carbamates as novel substance p 1-7 analogues.
AID1176532Inhibition of CYP3A4 (unknown origin)2014ACS medicinal chemistry letters, Dec-11, Volume: 5, Issue:12
Exploration and pharmacokinetic profiling of phenylalanine based carbamates as novel substance p 1-7 analogues.
AID756390Intrinsic clearance in human liver microsomes at 1 uM by LC/MS analysis2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Constrained H-Phe-Phe-NH2 analogues with high affinity to the substance P 1-7 binding site and with improved metabolic stability and cell permeability.
AID266249Binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells2006Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12
Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding.
AID462889Displacement of [Sar9, Met (O2)11]-SP from human recombinant NK1 receptor at 10 uM2010Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
Discovery of dipeptides with high affinity to the specific binding site for substance P1-7.
AID1176535Binding affinity to NK1 receptor (unknown origin)2014ACS medicinal chemistry letters, Dec-11, Volume: 5, Issue:12
Exploration and pharmacokinetic profiling of phenylalanine based carbamates as novel substance p 1-7 analogues.
AID1498740Displacement of [3H]SP1-7 from NK1 receptor in Sprague-Dawley rat spinal cord membranes after 60 mins by scintillation counting method2018Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14
An imidazole based H-Phe-Phe-NH
AID24002Half-life period at a substrate concentration of 262 uM was determined2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
The stability of pseudopeptides bearing sulfoximines as chiral backbone modifying element towards proteinase K.
AID756382Efflux ratio of permeability from basolateral to apical over apical to basolateral side in human Caco2 cells2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Constrained H-Phe-Phe-NH2 analogues with high affinity to the substance P 1-7 binding site and with improved metabolic stability and cell permeability.
AID462890Displacement of [MePhe7]-NKB from human recombinant NK2 receptor at 10 uM2010Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
Discovery of dipeptides with high affinity to the specific binding site for substance P1-7.
AID756385Ratio of drug uptake in CHO cells expressing PEPT1 to drug uptake in CHOK1 cells2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Constrained H-Phe-Phe-NH2 analogues with high affinity to the substance P 1-7 binding site and with improved metabolic stability and cell permeability.
AID1176505Drug recovery in rat plasma at 10 uM2014ACS medicinal chemistry letters, Dec-11, Volume: 5, Issue:12
Exploration and pharmacokinetic profiling of phenylalanine based carbamates as novel substance p 1-7 analogues.
AID756391Displacement of [3H]SP1-7 from substance P receptor (1 to 7 amino acids) binding site in Sprague-Dawley rat spinal cord membranes after 60 mins by liquid scintillation counting analysis2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Constrained H-Phe-Phe-NH2 analogues with high affinity to the substance P 1-7 binding site and with improved metabolic stability and cell permeability.
AID1176534Inhibition of CYP2C9 (unknown origin)2014ACS medicinal chemistry letters, Dec-11, Volume: 5, Issue:12
Exploration and pharmacokinetic profiling of phenylalanine based carbamates as novel substance p 1-7 analogues.
AID1176531Inhibition of CYP2D6 (unknown origin)2014ACS medicinal chemistry letters, Dec-11, Volume: 5, Issue:12
Exploration and pharmacokinetic profiling of phenylalanine based carbamates as novel substance p 1-7 analogues.
AID679004TP_TRANSPORTER: uptake in Xenopus laevis oocytes1998Journal of pharmaceutical sciences, Dec, Volume: 87, Issue:12
Improvement of L-dopa absorption by dipeptidyl derivation, utilizing peptide transporter PepT1.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (10.00)18.2507
2000's2 (20.00)29.6817
2010's7 (70.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.58 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.97 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]